Seeking Alpha

Leonard Yaffe's  Instablog

Leonard Yaffe
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • GILD--Stock Down On ESRX Comments 0 comments
    Dec 10, 2013 1:03 PM | about stocks: GILD, ABBV, JNJ, ESRX

    GILD's stock is down sharply on a comment by ESRX in regard to seeking lower pricing for the newer drugs to treat Hep C. I DO NOT view this as a significant threat to GILD's earnings stream. I have been assuming $60-70k per course of therapy. Pharmacoeconomic data exists that supports the cost-effectiveness of treating Hep C. Current Hep C drug therapy (less effective, more side effects) is $70k if one includes a PI. For 2014, the available drugs will include JNJ's simeprevir and GILD's sofosbuvir, and these may be recommended by the AASLD-IDSA joint panel to be used off label in Genotype 1 patients. Furthermore, the ABBV regimen discussed today, while all-oral, still includes ribavirin, which has side effects including anemia. I believe that the comments made by ESRX reflect the very large number of patients that they expect to be treated in the coming years. Len

    Disclosure: I am long GILD, JNJ, ABBV, ESRX.

Back To Leonard Yaffe's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.